Our patient treated with pembrolizumab and axitinib is one of the longest survivors in Japan on KEYNOTE 426, despite adverse events, including delayed-onset hepatitis. We herein present a detailed clinical course and short discussion on the case.
This was a 49-year-old male with clear cell renal cell carcinoma and lung metastases. After cytoreductive nephrectomy, treatment with pembrolizumab plus axitinib was initiated and the patient demonstrated a radiographic partial response as best response. The main adverse event was pembrolizumab-induced delayed-onset hepatitis, which was successfully treated with prednisolone. Pembrolizumab was re-initiated and completed.
The survival benefit in the present case may be due to the initial potent anti-cancer effects of axitinib and durable immune effects of pembrolizumab, leading to long-term treatment-free survival.
IJU case reports. 2022 Feb 18*** epublish ***
Koshiro Nishimoto, Suguru Shirotake, Yu Miyama, Go Kaneko, Kent Kanao, Daisuke Igarashi, Takayuki Takahashi, Yuta Umezawa, Masanori Yasuda, Masafumi Oyama
Department of Uro-Oncology Saitama Medical University International Medical Center Hidaka Saitama Japan., Department of Pathology Saitama Medical University International Medical Center Hidaka Saitama Japan.